title: Direct and indirect interactions between cannabinoid CB1 receptor and group II metabotropic glutamate receptor signalling in layer V pyramidal neurons from the rat prefrontal cortex.
abstract: At proximal synapses from layer V pyramidal neurons from the rat prefrontal cortex, activation of group II metabotropic glutamate receptors (group II mGlu) by (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl) glycine (DCG IV) induced a long-lasting depression of excitatory postsynaptic currents. Paired-pulse experiments suggested that the depression was expressed presynaptically. Activation of type 1 cannabinoid receptors (CB1) by WIN 55,212-2 occluded the DCG IV-induced depression in a mutually occlusive manner. At the postsynaptic level, WIN 55,212-2 and DCG IV were also occlusive for the activation of extracellular signal-regulated kinase. The postsynaptic localization of active extracellular signal-regulated kinase was confirmed by immunocytochemistry after activation of CB1 receptors. However, phosphorylation of extracellular signal-regulated kinase in layer V pyramidal neurons was dependent on the activation of N-methyl-d-aspartate receptors, consequently to a release of glutamate in the local network. Group II mGlu were also shown to be involved in long-term changes in synaptic plasticity induced by high frequency stimulations. The group II mGlu antagonist (RS)-alpha-methylserine-O-phosphate monophenyl ester (MSOPPE) favoured long-term depression. However, no interaction was found between MSOPPE, WIN 55,212-2 and the CB1 receptor antagonist SR 141716A on the modulation of long-term depression or long-term potentiation and the effects of these drugs were rather additive. We suggest that CB1 receptor and group II mGlu signalling may interact through a presynaptic mechanism in the induction of a DCG IV-induced depression. Postsynaptically, an indirect interaction occurs for activation of extracellular signal-regulated kinase. However, none of these interactions seem to play a role in synaptic plasticities induced with high frequency stimulations.
authors.affiliation: Neurobiologie des Processus Adaptatifs, CNRS-UMR 7102, 75005, Paris, France. jean-gael.barbara@snv.jussieu.fr
authors.forename: Jean-Gaël
authors.initials: JG
authors.lastname: Barbara
authors.forename: Nathalie
authors.initials: N
authors.lastname: Auclair
authors.forename: Marie-Paule
authors.initials: MP
authors.lastname: Roisin
authors.forename: Satoru
authors.initials: S
authors.lastname: Otani
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Valjent
authors.forename: Jocelyne
authors.initials: J
authors.lastname: Caboche
authors.forename: Philippe
authors.initials: P
authors.lastname: Soubrie
authors.forename: Francis
authors.initials: F
authors.lastname: Crepel
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D048588:Benzoxazines; D002121:Calcium Channel Blockers / Q000494:pharmacology; D003521:Cyclopropanes / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D007150:Immunohistochemistry; D017774:Long-Term Potentiation / Q000502:physiology; D020928:Mitogen-Activated Protein Kinases / Q000187:drug effects / Q000378:metabolism; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D009473:Neuronal Plasticity / Q000502:physiology*; D009924:Organ Culture Techniques; D010766:Phosphorylation; D010768:Phosphoserine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism; D017966:Pyramidal Cells / Q000187:drug effects / Q000378:metabolism*; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000187:drug effects / Q000378:metabolism*; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects / Q000378:metabolism*; D000077285:Rimonabant; D015398:Signal Transduction / Q000502:physiology
chemical_list: D000927:Anticonvulsants; D048588:Benzoxazines; D002121:Calcium Channel Blockers; D003521:Cyclopropanes; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D018094:Receptors, Metabotropic Glutamate; C442477:alpha-methylserine-O-phosphate monophenyl ester; C082313:2-(2,3-dicarboxycyclopropyl)glycine; D010768:Phosphoserine; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D020928:Mitogen-Activated Protein Kinases; D000077285:Rimonabant; D005998:Glycine